SYRE - Company ID 0001636282
The table below shows Spyre Therapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$57.37M | -$40.99M | -$28.54M | -$17.63M | -$26.26M | -$19.53M |
| Capital expenditure | - | - | - | - | $37.00K | $450.00K |
| Investing cash flow | $56.58M | -$61.00K | -$104.96M | $17.75M | $25.76M | $9.30M |
| Dividends paid | - | - | - | - |
Spyre Therapeutics, Inc. reported operating cash flow of -$169.25M for fiscal year 2025. That is down 7.5% from -$157.41M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$18.84M (FY 2016) to -$169.25M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $12.26M | $125.00K | $172.16M | $10.00K | $12.00K | $362.00K |